Melane Sampson, Author at BioTuesdays

Executive Moves

enGene appoints Amy Pott as chief global commercialization officer

enGene Holdings (NASDAQ: ENGN) announced the appointment of Amy Pott as chief global commercialization officer—the company’s first dedicated executive for commercialization endeavors—reporting to Ron Cooper, CEO of...

May 28, 2025

Executive Moves

CellCentric appoints Celia Economides as CFO & CBO

Closely held CellCentric has announced that it is expanding its leadership team with the appointment of Celia Economides as Chief Financial Officer & Chief Business Officer (CFO & CBO). According...

May 27, 2025

Feature

Eledon leading a paradigm shift in immunosuppression therapy in organ transplantation

Eledon Pharmaceuticals (NASDAQ: ELDN) is pioneering a potential breakthrough in immunosuppression therapy aimed at extending the longevity of transplanted organs and enhancing the overall health and quality of life for...

May 27, 2025

Developments

Perimeter partners with Intermountain Health to study benefits of using OCT and AI to reduce cancer reoperations

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has entered into a development support agreement with Intermountain Health, creating the framework for the two organizations to partner on a...

May 23, 2025

Executive Moves

Scienture announces executive leadership transition

Scienture Holdings (NASDAQ: SCNX) announced that Suren Ajjarapu, CEO and chairman of the board, has stepped down. The management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani will assume these roles. Shankar...

May 22, 2025

Developments

FDA clears Quoin’s second QRX003 NS pivotal study

Quoin Pharmaceuticals (NASDAQ: QNRX) announced that the FDA has provided clearance to initiate a second Netherton Syndrome (NS) clinical pivotal study—CL-QRX003-002, for Quoin’s lead product QRX003. According to Quoin...

May 22, 2025

Developments

NorthStrive completes Phase 1 review for oral myostatin-engineered probiotic

NorthStrive Biosciences (NASDAQ:ELAB) announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic targeting...

May 22, 2025

Developments

Zura Bio launches global Phase 2 study of tibulizumab in HS

Zura Bio (NASDAQ:ZURA) announced that it has launched a global Phase 2 study—TibuSHIELD—to evaluate tibulizumab in 180 adults with moderate to severe hidradenitis suppurativa (HS) across Canada, the U.S. and Europe...

May 21, 2025

Feature

Longhorn impacting global health challenges by tackling bacterial toxins with vaccine and diagnostics solutions

Closely held Longhorn Vaccines and Diagnostics is developing peptide vaccines and monoclonal antibodies aimed at preventing and reducing the global burden of medical conditions caused by key bacterial toxins, including...

May 20, 2025

Developments

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

Neurogene (NASDAQ:NGNE) has announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) annual meeting this week describing a monitoring and treatment algorithm intended to reverse the rare...

May 16, 2025

Author - Melane Sampson

enGene appoints Amy Pott as chief global commercialization officer

CellCentric appoints Celia Economides as CFO & CBO

Eledon leading a paradigm shift in immunosuppression therapy in organ transplantation

Perimeter partners with Intermountain Health to study benefits of using OCT and AI to reduce cancer reoperations

Scienture announces executive leadership transition

FDA clears Quoin’s second QRX003 NS pivotal study

NorthStrive completes Phase 1 review for oral myostatin-engineered probiotic

Zura Bio launches global Phase 2 study of tibulizumab in HS

Longhorn impacting global health challenges by tackling bacterial toxins with vaccine and diagnostics solutions

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

Subscribe